# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 13.6 | 95.8 | (51.0-163.9) |  | Male | 11 | 9.4 | 116.5 | (58.1-208.5) |
| Female | 7 | 5.6 | 125.2 | (50.1-257.9) |  | Female | 10 | 8.6 | 116.2 | (55.7-213.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 6 | 3.0 | 198.9 | (72.6-432.9) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 1 | 8.4 | nc | (nc-nc) |
| Female | 62 | 68.8 | 90.1 | (69.1-115.5) |  | Female | 4 | 8.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.6 | 65.6 | (21.1-153.1) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 6 | 3.6 | 167.0 | (61.0-363.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 15.7 | 133.4 | (82.6-203.9) |  |  |  |  |  |  |
| Female | 22 | 16.6 | 132.3 | (82.9-200.3) |  | Female | 4 | 5.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.9 | 129.3 | (41.7-301.7) |  | Male | 8 | 5.1 | 155.9 | (67.1-307.3) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 51 | 49.7 | 102.6 | (76.4-134.9) |
| Female | 3 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 8.7 | 195.2 | (113.7-312.6) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 7 | 5.3 | 131.6 | (52.7-271.2) |  | Female | 5 | 2.3 | 220.3 | (71.0-514.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 6 | 0.7 | 801.6 | (292.7-1744.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.8 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 7 | 4.9 | 143.0 | (57.3-294.6) |  | Female | 12 | 13.6 | 88.0 | (45.4-153.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.5 | 109.2 | (39.9-237.6) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 17 | 16.0 | 106.5 | (62.0-170.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 25.1 | 155.4 | (110.5-212.4) |  | Male | 222 | 193.1 | 114.9 | (100.3-131.1) |
| Female | 38 | 29.6 | 128.2 | (90.7-176.0) |  | Female | 245 | 225.3 | 108.7 | (95.6-123.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

10

# Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 19.5 | 97.3 | (58.6-152.0) |  | Male | 15 | 13.8 | 108.7 | (60.8-179.2) |
| Female | 5 | 7.3 | 68.1 | (22.0-159.0) |  | Female | 16 | 11.3 | 141.5 | (80.8-229.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 4.4 | 157.5 | (63.1-324.6) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 5 | 3.5 | 142.0 | (45.8-331.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 16 | 12.4 | 129.1 | (73.7-209.6) |
| Female | 114 | 94.7 | 120.3 | (99.3-144.6) |  | Female | 12 | 10.9 | 109.7 | (56.6-191.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 11.3 | 114.6 | (60.9-195.9) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 5 | 4.8 | 104.7 | (33.8-244.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 23.9 | 79.5 | (47.8-124.1) |  |  |  |  |  |  |
| Female | 22 | 22.9 | 95.9 | (60.1-145.2) |  | Female | 10 | 8.0 | 125.6 | (60.1-231.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.5 | 126.8 | (50.8-261.3) |  | Male | 6 | 7.5 | 80.5 | (29.4-175.1) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.5 | 93.2 | (37.3-192.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 79 | 69.4 | 113.8 | (90.1-141.8) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 12.8 | nc | (nc-nc) |  | Male | 1 | 5.1 | nc | (nc-nc) |
| Female | 9 | 7.2 | 125.8 | (57.4-238.9) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.6 | 58.2 | (18.7-135.8) |  | Male | 6 | 6.4 | 94.4 | (34.5-205.5) |
| Female | 10 | 6.3 | 159.1 | (76.2-292.6) |  | Female | 17 | 18.1 | 93.8 | (54.6-150.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 8.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 16 | 20.8 | 76.8 | (43.9-124.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 35.6 | 42.2 | (23.6-69.6) |  | Male | 236 | 279.3 | 84.5 | (74.0-96.0) |
| Female | 31 | 39.5 | 78.4 | (53.3-111.3) |  | Female | 319 | 302.4 | 105.5 | (94.2-117.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

11

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 12.2 | 172.4 | (106.7-263.6) |  | Male | 6 | 7.7 | 78.1 | (28.5-169.9) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 5 | 5.9 | 84.6 | (27.3-197.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 9 | 6.9 | 130.3 | (59.5-247.4) |
| Female | 46 | 48.9 | 94.1 | (68.9-125.5) |  | Female | 8 | 6.2 | 128.3 | (55.2-252.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 13.1 | 122.4 | (69.9-198.9) |  |  |  |  |  |  |
| Female | 13 | 13.1 | 99.3 | (52.8-169.9) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 5 | 4.3 | 115.8 | (37.3-270.2) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.6 | 108.2 | (34.9-252.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 39 | 36.6 | 106.5 | (75.7-145.6) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 6.7 | 105.2 | (42.1-216.7) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 8 | 3.5 | 228.3 | (98.3-449.8) |  | Female | 7 | 8.4 | 83.3 | (33.4-171.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 9 | 10.8 | 83.0 | (37.9-157.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 21.1 | 132.7 | (88.2-191.8) |  | Male | 173 | 154.7 | 111.8 | (95.8-129.8) |
| Female | 22 | 23.9 | 91.9 | (57.6-139.2) |  | Female | 153 | 164.9 | 92.8 | (78.7-108.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

12

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.5 | 105.6 | (50.6-194.2) |  | Male | 3 | 5.9 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 5 | 5.1 | 98.3 | (31.7-229.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 4 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.4 | 130.8 | (52.4-269.5) |
| Female | 34 | 41.9 | 81.2 | (56.2-113.5) |  | Female | 7 | 5.4 | 130.3 | (52.2-268.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.5 | 111.5 | (35.9-260.1) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 10.2 | 88.2 | (40.3-167.5) |  |  |  |  |  |  |
| Female | 10 | 11.3 | 88.4 | (42.3-162.6) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 30 | 30.3 | 98.9 | (66.7-141.2) |
| Female | 2 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.8 | 131.2 | (42.3-306.1) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 7 | 7.2 | 97.6 | (39.1-201.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 7 | 9.3 | 75.4 | (30.2-155.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 16.8 | 143.2 | (91.7-213.1) |  | Male | 129 | 122.3 | 105.5 | (88.1-125.3) |
| Female | 25 | 20.9 | 119.9 | (77.6-177.0) |  | Female | 130 | 142.0 | 91.6 | (76.5-108.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

13

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 31.8 | 110.0 | (76.6-152.9) |  | Male | 21 | 20.4 | 103.1 | (63.8-157.6) |
| Female | 10 | 13.9 | 72.1 | (34.5-132.6) |  | Female | 15 | 17.7 | 84.5 | (47.3-139.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  | Male | 11 | 6.6 | 166.3 | (82.9-297.6) |
| Female | 5 | 5.6 | 90.0 | (29.0-210.0) |  | Female | 7 | 6.2 | 112.8 | (45.2-232.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 24 | 18.3 | 131.3 | (84.1-195.3) |
| Female | 142 | 141.7 | 100.2 | (84.4-118.1) |  | Female | 17 | 18.8 | 90.3 | (52.6-144.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 15.5 | 148.0 | (93.8-222.1) |
| Female | 7 | 4.5 | 155.8 | (62.4-321.0) |  | Female | 13 | 7.8 | 166.1 | (88.4-284.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 34.5 | 124.6 | (90.1-167.8) |  |  |  |  |  |  |
| Female | 34 | 40.6 | 83.8 | (58.0-117.1) |  | Female | 8 | 12.4 | 64.6 | (27.8-127.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 8.4 | nc | (nc-nc) |  | Male | 10 | 11.5 | 86.9 | (41.6-159.8) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 17 | 14.3 | 119.0 | (69.3-190.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 88 | 104.3 | 84.4 | (67.7-104.0) |
| Female | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 18.1 | 149.1 | (98.3-217.0) |  | Male | 9 | 7.7 | 116.5 | (53.2-221.1) |
| Female | 6 | 11.4 | 52.6 | (19.2-114.4) |  | Female | 5 | 5.5 | 90.2 | (29.1-210.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.9 | 142.6 | (57.1-293.7) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 13.0 | 84.9 | (42.3-151.9) |  | Male | 5 | 8.0 | 62.3 | (20.1-145.4) |
| Female | 9 | 10.8 | 83.0 | (37.9-157.6) |  | Female | 18 | 24.3 | 74.0 | (43.8-116.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 11.4 | 113.7 | (60.5-194.5) |  |  |  |  |  |  |
| Female | 5 | 4.4 | 113.1 | (36.4-263.9) |  | Female | 24 | 31.6 | 76.0 | (48.7-113.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 57.2 | 143.4 | (114.0-178.0) |  | Male | 448 | 418.2 | 107.1 | (97.4-117.5) |
| Female | 88 | 69.8 | 126.0 | (101.1-155.3) |  | Female | 473 | 489.5 | 96.6 | (88.1-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

14

# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 4 | 12.3 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 7 | 10.5 | 66.9 | (26.8-137.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

15

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 14.3 | 126.3 | (74.8-199.6) |  | Male | 8 | 10.3 | 77.9 | (33.5-153.5) |
| Female | 10 | 5.8 | 171.9 | (82.3-316.2) |  | Female | 5 | 8.8 | 56.7 | (18.3-132.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 6 | 2.7 | 219.1 | (80.0-476.8) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 12 | 9.1 | 131.4 | (67.8-229.5) |
| Female | 76 | 72.2 | 105.3 | (83.0-131.8) |  | Female | 10 | 8.6 | 117.0 | (56.0-215.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.5 | 106.4 | (48.5-201.9) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 17.1 | 111.3 | (67.0-173.8) |  |  |  |  |  |  |
| Female | 20 | 17.7 | 113.1 | (69.1-174.7) |  | Female | 6 | 6.1 | 98.9 | (36.1-215.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 8 | 5.5 | 145.2 | (62.5-286.2) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.9 | 118.7 | (47.5-244.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 71 | 52.8 | 134.5 | (105.0-169.6) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 9.6 | 52.3 | (16.9-122.1) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 5 | 5.5 | 90.3 | (29.1-210.6) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.4 | 140.2 | (64.0-266.2) |  | Male | 6 | 4.8 | 125.1 | (45.7-272.3) |
| Female | 8 | 4.9 | 164.8 | (71.0-324.8) |  | Female | 18 | 14.0 | 128.3 | (76.0-202.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.0 | 115.7 | (46.4-238.5) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 13 | 16.0 | 81.4 | (43.3-139.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 26.4 | 117.4 | (79.8-166.7) |  | Male | 238 | 207.9 | 114.5 | (100.4-130.0) |
| Female | 40 | 31.0 | 128.9 | (92.1-175.5) |  | Female | 247 | 233.5 | 105.8 | (93.0-119.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

16

# Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 18.3 | 81.9 | (45.8-135.0) |  | Male | 13 | 12.1 | 107.7 | (57.3-184.2) |
| Female | 2 | 7.2 | nc | (nc-nc) |  | Female | 14 | 11.4 | 122.5 | (66.9-205.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 6 | 11.8 | 50.9 | (18.6-110.8) |
| Female | 77 | 76.5 | 100.7 | (79.4-125.8) |  | Female | 13 | 10.7 | 121.6 | (64.7-208.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 8.7 | 103.5 | (47.3-196.6) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 19.6 | 71.3 | (39.0-119.7) |  |  |  |  |  |  |
| Female | 27 | 20.9 | 129.2 | (85.1-188.0) |  | Female | 9 | 7.4 | 122.3 | (55.8-232.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.6 | nc | (nc-nc) |  | Male | 9 | 6.4 | 139.8 | (63.8-265.5) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.1 | 98.3 | (39.4-202.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 4.0 | nc | (nc-nc) |  | Male | 42 | 55.7 | 75.4 | (54.3-101.9) |
| Female | 0 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 10.1 | 49.7 | (16.0-116.0) |  | Male | 0 | 4.4 | nc | (nc-nc) |
| Female | 7 | 6.3 | 110.9 | (44.4-228.5) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 1 | 7.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 9.2 | 98.0 | (44.7-186.0) |  | Male | 7 | 5.7 | 123.7 | (49.5-254.8) |
| Female | 2 | 7.0 | nc | (nc-nc) |  | Female | 3 | 20.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 13 | 17.3 | 75.2 | (40.0-128.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 32.6 | 43.0 | (23.5-72.2) |  | Male | 169 | 250.0 | 67.6 | (57.8-78.6) |
| Female | 17 | 37.3 | 45.6 | (26.5-73.0) |  | Female | 219 | 278.6 | 78.6 | (68.5-89.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

17

# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 35.1 | 71.3 | (46.1-105.3) |  | Male | 26 | 22.6 | 115.0 | (75.1-168.5) |
| Female | 9 | 12.3 | 73.1 | (33.4-138.8) |  | Female | 28 | 18.1 | 155.1 | (103.0-224.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.0 | 114.6 | (49.3-225.8) |  | Male | 7 | 7.4 | 94.3 | (37.8-194.3) |
| Female | 5 | 5.9 | 84.6 | (27.3-197.5) |  | Female | 12 | 5.8 | 207.3 | (107.0-362.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 29 | 20.4 | 142.3 | (95.3-204.4) |
| Female | 158 | 150.2 | 105.2 | (89.4-122.9) |  | Female | 18 | 17.9 | 100.4 | (59.4-158.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 17.5 | 91.2 | (52.1-148.2) |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 2 | 7.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 38.7 | 80.1 | (54.4-113.7) |  |  |  |  |  |  |
| Female | 39 | 37.3 | 104.6 | (74.4-143.1) |  | Female | 12 | 12.7 | 94.2 | (48.6-164.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 9.4 | 96.0 | (43.8-182.2) |  | Male | 13 | 12.7 | 102.4 | (54.5-175.1) |
| Female | 7 | 2.4 | 286.2 | (114.7-589.8) |  | Female | 13 | 12.6 | 103.3 | (54.9-176.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 107 | 116.6 | 91.8 | (75.2-110.9) |
| Female | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 20.4 | 93.0 | (55.9-145.2) |  | Male | 5 | 8.6 | 58.3 | (18.8-136.1) |
| Female | 12 | 11.6 | 103.4 | (53.4-180.7) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  | Male | 8 | 4.3 | 188.2 | (81.0-370.8) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 14.4 | 124.8 | (73.9-197.2) |  | Male | 14 | 9.1 | 153.4 | (83.8-257.3) |
| Female | 11 | 10.4 | 106.3 | (53.0-190.1) |  | Female | 42 | 28.0 | 150.0 | (108.1-202.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 12.8 | 62.4 | (26.9-122.9) |  |  |  |  |  |  |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 25 | 33.4 | 74.9 | (48.4-110.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 63.4 | 63.1 | (45.0-85.9) |  | Male | 421 | 466.2 | 90.3 | (81.9-99.4) |
| Female | 40 | 66.2 | 60.5 | (43.2-82.3) |  | Female | 476 | 488.4 | 97.5 | (88.9-106.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

18

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

19

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 45.7 | 102.9 | (75.6-136.8) |  | Male | 27 | 29.4 | 91.9 | (60.5-133.7) |
| Female | 17 | 18.4 | 92.5 | (53.8-148.0) |  | Female | 24 | 25.5 | 94.1 | (60.3-140.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 9.0 | 100.3 | (45.8-190.4) |  | Male | 11 | 9.3 | 118.1 | (58.9-211.4) |
| Female | 9 | 7.9 | 114.0 | (52.0-216.4) |  | Female | 5 | 8.4 | 59.6 | (19.2-139.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 19 | 26.5 | 71.8 | (43.2-112.2) |
| Female | 209 | 201.8 | 103.6 | (90.0-118.6) |  | Female | 32 | 25.8 | 123.9 | (84.7-174.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 21.6 | 83.5 | (49.5-132.0) |
| Female | 5 | 7.0 | 71.3 | (23.0-166.4) |  | Female | 14 | 10.9 | 129.0 | (70.5-216.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 44 | 50.3 | 87.4 | (63.5-117.4) |  |  |  |  |  |  |
| Female | 52 | 55.0 | 94.6 | (70.7-124.1) |  | Female | 17 | 17.4 | 97.5 | (56.8-156.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 11.5 | 95.6 | (47.6-171.0) |  | Male | 18 | 16.3 | 110.4 | (65.4-174.4) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 16 | 18.9 | 84.5 | (48.3-137.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 136 | 136.6 | 99.6 | (83.5-117.8) |
| Female | 6 | 2.9 | 207.3 | (75.7-451.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 25.5 | 105.9 | (69.8-154.1) |  | Male | 10 | 11.1 | 90.0 | (43.1-165.5) |
| Female | 11 | 15.9 | 69.0 | (34.4-123.5) |  | Female | 7 | 7.5 | 93.3 | (37.4-192.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 6.7 | 74.8 | (24.1-174.6) |  | Male | 7 | 6.7 | 105.2 | (42.2-216.8) |
| Female | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 18.8 | 95.7 | (56.7-151.3) |  | Male | 13 | 12.0 | 108.3 | (57.6-185.2) |
| Female | 12 | 15.0 | 80.2 | (41.4-140.1) |  | Female | 38 | 37.8 | 100.6 | (71.2-138.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 15.7 | 95.7 | (53.5-157.9) |  |  |  |  |  |  |
| Female | 4 | 6.0 | nc | (nc-nc) |  | Female | 46 | 44.7 | 103.0 | (75.4-137.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 73 | 79.7 | 91.6 | (71.8-115.2) |  | Male | 558 | 585.9 | 95.2 | (87.5-103.5) |
| Female | 91 | 93.7 | 97.1 | (78.2-119.2) |  | Female | 677 | 682.8 | 99.2 | (91.8-106.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

20

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.0 | 100.0 | (32.2-233.3) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 19 | 28.0 | 67.9 | (40.9-106.1) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 6.0 | 116.5 | (46.7-240.0) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 21 | 21.2 | 98.9 | (61.2-151.2) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 2.3 | 261.7 | (95.5-569.5) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 9.6 | 72.7 | (29.1-149.8) |  | Male | 71 | 77.8 | 91.3 | (71.3-115.1) |
| Female | 4 | 11.3 | nc | (nc-nc) |  | Female | 64 | 86.1 | 74.3 | (57.2-94.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

21

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 13 | 14.7 | 88.4 | (47.0-151.2) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 8 | 11.3 | 70.9 | (30.5-139.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 41 | 45.6 | 90.0 | (64.6-122.1) |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 42 | 47.4 | 88.7 | (63.9-119.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

22

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 6 | 9.6 | 62.7 | (22.9-136.4) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 18 | 23.2 | 77.7 | (46.0-122.9) |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 20 | 31.3 | 63.8 | (39.0-98.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

23

# Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 16.1 | 112.1 | (66.4-177.2) |  | Male | 6 | 10.9 | 54.8 | (20.0-119.3) |
| Female | 4 | 6.1 | nc | (nc-nc) |  | Female | 3 | 9.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 9.8 | 81.5 | (35.1-160.6) |
| Female | 62 | 73.7 | 84.1 | (64.5-107.9) |  | Female | 6 | 8.9 | 67.3 | (24.6-146.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.8 | 57.1 | (18.4-133.2) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 5 | 3.8 | 130.5 | (42.1-304.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 18.6 | 59.3 | (29.5-106.1) |  |  |  |  |  |  |
| Female | 21 | 18.2 | 115.5 | (71.5-176.6) |  | Female | 7 | 6.3 | 111.5 | (44.7-229.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 4.4 | 225.9 | (108.2-415.5) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 6 | 6.2 | 96.3 | (35.2-209.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 40 | 56.1 | 71.3 | (51.0-97.2) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 10.0 | 49.9 | (16.1-116.5) |  | Male | 6 | 4.0 | 148.2 | (54.1-322.6) |
| Female | 1 | 5.7 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 6.9 | nc | (nc-nc) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 6 | 5.2 | 116.1 | (42.4-252.7) |  | Female | 21 | 14.0 | 150.2 | (93.0-229.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.3 | 79.3 | (25.6-185.1) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 15 | 16.8 | 89.1 | (49.8-146.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 29.1 | 82.3 | (52.7-122.5) |  | Male | 168 | 223.0 | 75.3 | (64.4-87.6) |
| Female | 41 | 32.5 | 126.1 | (90.5-171.1) |  | Female | 224 | 241.5 | 92.8 | (81.0-105.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

24

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 14.6 | 123.4 | (73.1-195.1) |  | Male | 6 | 9.3 | 64.4 | (23.5-140.1) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 3 | 6.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 2 | 8.2 | nc | (nc-nc) |
| Female | 44 | 49.7 | 88.5 | (64.3-118.8) |  | Female | 5 | 6.3 | 79.9 | (25.7-186.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 7.1 | 99.2 | (39.7-204.4) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 15.4 | 110.6 | (64.4-177.1) |  |  |  |  |  |  |
| Female | 14 | 13.0 | 107.3 | (58.6-180.1) |  | Female | 1 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 4 | 5.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.5 | 110.0 | (35.5-256.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 26 | 48.1 | 54.1 | (35.3-79.3) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 8.2 | 122.5 | (58.7-225.3) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 5 | 3.6 | 139.5 | (45.0-325.6) |  | Female | 11 | 9.1 | 121.2 | (60.4-217.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 20 | 11.4 | 175.6 | (107.2-271.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 26.8 | 138.2 | (97.3-190.5) |  | Male | 167 | 191.2 | 87.3 | (74.6-101.6) |
| Female | 32 | 23.0 | 138.9 | (95.0-196.2) |  | Female | 174 | 166.7 | 104.4 | (89.4-121.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

25

# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 41 | 42.0 | 97.6 | (70.1-132.5) |  | Male | 27 | 27.9 | 96.7 | (63.7-140.7) |
| Female | 17 | 15.1 | 112.9 | (65.8-180.8) |  | Female | 23 | 22.3 | 103.3 | (65.4-154.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 8.9 | 78.7 | (31.5-162.2) |  | Male | 6 | 8.9 | 67.6 | (24.7-147.1) |
| Female | 7 | 7.2 | 97.5 | (39.1-201.0) |  | Female | 7 | 7.0 | 99.9 | (40.0-205.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 13 | 25.1 | 51.8 | (27.6-88.7) |
| Female | 184 | 179.4 | 102.5 | (88.3-118.5) |  | Female | 17 | 21.8 | 78.1 | (45.5-125.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 21.3 | 98.6 | (61.0-150.7) |
| Female | 5 | 6.3 | 79.8 | (25.7-186.3) |  | Female | 12 | 9.3 | 128.9 | (66.5-225.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 55 | 47.2 | 116.5 | (87.8-151.7) |  |  |  |  |  |  |
| Female | 46 | 45.0 | 102.3 | (74.9-136.5) |  | Female | 22 | 15.4 | 143.2 | (89.7-216.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 11.1 | 116.8 | (62.1-199.8) |  | Male | 21 | 15.3 | 137.4 | (85.0-210.1) |
| Female | 5 | 3.0 | 168.2 | (54.2-392.5) |  | Female | 17 | 15.2 | 111.5 | (64.9-178.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 3.6 | 191.9 | (76.9-395.3) |  | Male | 142 | 136.1 | 104.3 | (87.9-123.0) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 25.0 | 68.0 | (39.6-108.8) |  | Male | 5 | 10.4 | 48.2 | (15.5-112.5) |
| Female | 12 | 14.0 | 85.6 | (44.2-149.6) |  | Female | 8 | 6.1 | 131.6 | (56.7-259.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 6.5 | 153.8 | (73.6-282.8) |  | Male | 10 | 6.9 | 145.0 | (69.4-266.7) |
| Female | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 17.9 | 83.9 | (46.9-138.5) |  | Male | 10 | 12.0 | 83.2 | (39.8-153.0) |
| Female | 8 | 12.8 | 62.5 | (26.9-123.3) |  | Female | 24 | 35.1 | 68.3 | (43.8-101.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 15.3 | 72.1 | (35.9-128.9) |  |  |  |  |  |  |
| Female | 11 | 5.1 | 216.2 | (107.8-386.8) |  | Female | 48 | 40.0 | 120.1 | (88.6-159.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 99 | 75.6 | 131.0 | (106.5-159.5) |  | Male | 571 | 563.2 | 101.4 | (93.2-110.1) |
| Female | 78 | 80.5 | 96.9 | (76.6-120.9) |  | Female | 614 | 591.6 | 103.8 | (95.7-112.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

26

# Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 19.4 | 139.2 | (91.7-202.6) |  | Male | 15 | 12.0 | 124.7 | (69.8-205.8) |
| Female | 11 | 8.0 | 137.0 | (68.3-245.2) |  | Female | 11 | 10.3 | 106.9 | (53.3-191.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 5 | 3.9 | 127.3 | (41.0-297.1) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 8 | 3.6 | 221.7 | (95.4-436.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 11 | 10.9 | 101.3 | (50.5-181.2) |
| Female | 83 | 83.5 | 99.5 | (79.2-123.3) |  | Female | 13 | 11.0 | 118.3 | (62.9-202.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 8.8 | 124.7 | (62.2-223.1) |
| Female | 0 | 2.6 | nc | (nc-nc) |  | Female | 1 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 20.8 | 96.2 | (58.7-148.5) |  |  |  |  |  |  |
| Female | 20 | 23.6 | 84.8 | (51.8-130.9) |  | Female | 7 | 7.2 | 96.7 | (38.7-199.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.9 | 123.1 | (44.9-267.9) |  | Male | 6 | 6.9 | 87.6 | (32.0-190.6) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 6 | 8.3 | 72.5 | (26.5-157.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 56 | 58.7 | 95.4 | (72.1-123.9) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 10.5 | 95.6 | (45.7-175.7) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 5 | 6.6 | 75.2 | (24.2-175.6) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 2.8 | 281.8 | (121.4-555.4) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.6 | 92.1 | (36.9-189.8) |  | Male | 5 | 4.6 | 109.6 | (35.3-255.7) |
| Female | 6 | 6.2 | 96.3 | (35.2-209.7) |  | Female | 13 | 14.2 | 91.6 | (48.7-156.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.4 | 108.7 | (43.5-224.0) |  |  |  |  |  |  |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 22 | 18.4 | 119.4 | (74.8-180.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 34.2 | 108.0 | (76.1-148.9) |  | Male | 266 | 244.4 | 108.8 | (96.1-122.7) |
| Female | 39 | 40.8 | 95.6 | (68.0-130.7) |  | Female | 282 | 285.8 | 98.7 | (87.5-110.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

27

# Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 5.2 | 171.8 | (78.4-326.2) |  | Male | 5 | 3.2 | 154.1 | (49.7-359.6) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 8 | 2.9 | 273.4 | (117.7-538.7) |
| Female | 26 | 21.8 | 119.5 | (78.1-175.1) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.6 | 88.9 | (28.7-207.6) |  |  |  |  |  |  |
| Female | 5 | 5.6 | 88.8 | (28.6-207.1) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 9 | 16.9 | 53.4 | (24.4-101.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 1.8 | 275.0 | (88.6-641.7) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 5.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 9.2 | 130.8 | (67.5-228.5) |  | Male | 78 | 67.4 | 115.8 | (91.5-144.5) |
| Female | 14 | 10.9 | 128.6 | (70.2-215.8) |  | Female | 74 | 73.6 | 100.6 | (79.0-126.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

28

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 6.6 | 105.5 | (42.2-217.3) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 35 | 29.9 | 117.2 | (81.6-163.0) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 7.7 | 78.3 | (28.6-170.5) |  |  |  |  |  |  |
| Female | 11 | 7.6 | 145.0 | (72.3-259.6) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 1.8 | 325.3 | (118.8-708.0) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 20 | 22.2 | 90.1 | (55.0-139.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 12 | 6.2 | 192.3 | (99.3-336.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 12.4 | 145.1 | (86.0-229.4) |  | Male | 87 | 93.0 | 93.5 | (74.9-115.4) |
| Female | 19 | 13.5 | 140.3 | (84.4-219.1) |  | Female | 121 | 98.8 | 122.5 | (101.6-146.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

29

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 98 | 68.4 | 143.3 | (116.3-174.6) |  | Male | 60 | 41.1 | 145.9 | (111.4-187.8) |
| Female | 28 | 23.4 | 119.7 | (79.5-172.9) |  | Female | 44 | 28.9 | 152.3 | (110.7-204.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 11.4 | 122.7 | (67.0-205.9) |  | Male | 9 | 13.4 | 66.9 | (30.5-127.0) |
| Female | 10 | 9.2 | 108.6 | (52.0-199.8) |  | Female | 13 | 10.5 | 124.4 | (66.2-212.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 46 | 36.6 | 125.6 | (91.9-167.5) |
| Female | 312 | 242.9 | 128.4 | (114.6-143.5) |  | Female | 43 | 31.4 | 136.8 | (99.0-184.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 32 | 29.8 | 107.2 | (73.3-151.4) |
| Female | 8 | 7.1 | 113.3 | (48.8-223.3) |  | Female | 16 | 13.1 | 121.9 | (69.6-197.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 59 | 69.5 | 84.9 | (64.6-109.6) |  |  |  |  |  |  |
| Female | 60 | 64.8 | 92.6 | (70.6-119.1) |  | Female | 21 | 21.0 | 99.9 | (61.8-152.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 17.2 | 122.4 | (75.7-187.1) |  | Male | 31 | 23.9 | 129.6 | (88.1-184.0) |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 19 | 23.5 | 80.9 | (48.7-126.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 236 | 209.4 | 112.7 | (98.8-128.0) |
| Female | 0 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 32 | 35.1 | 91.1 | (62.3-128.6) |  | Male | 18 | 16.0 | 112.4 | (66.6-177.7) |
| Female | 19 | 19.8 | 95.8 | (57.7-149.7) |  | Female | 10 | 8.8 | 113.5 | (54.3-208.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 9.9 | 60.5 | (22.1-131.7) |  | Male | 7 | 6.2 | 113.8 | (45.6-234.5) |
| Female | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 26.0 | 115.6 | (77.9-165.0) |  | Male | 10 | 14.2 | 70.2 | (33.6-129.1) |
| Female | 27 | 17.6 | 153.3 | (101.0-223.1) |  | Female | 28 | 38.3 | 73.2 | (48.6-105.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 22.6 | 119.3 | (78.6-173.5) |  |  |  |  |  |  |
| Female | 6 | 7.6 | 79.1 | (28.9-172.1) |  | Female | 43 | 56.0 | 76.8 | (55.6-103.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 91 | 121.6 | 74.8 | (60.3-91.9) |  | Male | 919 | 846.8 | 108.5 | (101.6-115.8) |
| Female | 111 | 124.7 | 89.0 | (73.2-107.2) |  | Female | 885 | 826.5 | 107.1 | (100.1-114.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

30

# Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.0 | 120.4 | (44.0-262.1) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 17 | 23.4 | 72.7 | (42.3-116.3) |  | Female | 0 | 2.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 5.8 | 172.6 | (82.6-317.4) |  |  |  |  |  |  |
| Female | 2 | 6.2 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 16 | 18.0 | 89.0 | (50.8-144.5) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 7 | 5.2 | 133.6 | (53.5-275.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 8.9 | 78.6 | (31.5-162.0) |  | Male | 60 | 69.9 | 85.8 | (65.5-110.5) |
| Female | 6 | 10.5 | 57.3 | (20.9-124.6) |  | Female | 61 | 77.6 | 78.6 | (60.1-101.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

31

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.2 | 158.5 | (51.1-369.8) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 9 | 10.4 | 86.4 | (39.4-164.1) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.1 | 159.2 | (51.3-371.5) |  |  |  |  |  |  |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 9.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.6 | 88.5 | (28.5-206.6) |  | Male | 33 | 38.1 | 86.7 | (59.7-121.8) |
| Female | 5 | 5.0 | 100.9 | (32.5-235.5) |  | Female | 27 | 33.9 | 79.7 | (52.5-115.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

32

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 18.0 | 100.2 | (59.3-158.3) |  | Male | 14 | 10.8 | 129.0 | (70.5-216.5) |
| Female | 5 | 6.0 | 83.5 | (26.9-194.9) |  | Female | 4 | 7.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.1 | 159.8 | (51.5-372.9) |  | Male | 5 | 3.5 | 144.7 | (46.6-337.8) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 15 | 9.7 | 155.3 | (86.8-256.1) |
| Female | 67 | 62.9 | 106.5 | (82.5-135.2) |  | Female | 9 | 8.2 | 110.1 | (50.2-208.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.4 | 107.8 | (46.4-212.4) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 18.7 | 80.4 | (45.0-132.6) |  |  |  |  |  |  |
| Female | 15 | 17.7 | 84.9 | (47.5-140.1) |  | Female | 1 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 8 | 6.1 | 130.4 | (56.2-257.0) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 7 | 6.1 | 114.8 | (46.0-236.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 58 | 45.9 | 126.3 | (95.9-163.3) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 8.8 | 90.5 | (39.0-178.3) |  | Male | 6 | 4.2 | 142.5 | (52.0-310.2) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.0 | 142.5 | (68.2-262.1) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 7 | 4.8 | 147.3 | (59.0-303.5) |  | Female | 11 | 11.0 | 100.1 | (49.9-179.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 6 | 13.6 | 44.2 | (16.1-96.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 30.9 | 90.7 | (60.2-131.1) |  | Male | 226 | 212.5 | 106.4 | (92.9-121.2) |
| Female | 26 | 30.6 | 84.9 | (55.5-124.5) |  | Female | 187 | 214.8 | 87.1 | (75.0-100.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

33

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 14.5 | 68.8 | (32.9-126.5) |  | Male | 6 | 10.0 | 60.1 | (21.9-130.8) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 6 | 7.3 | 82.1 | (30.0-178.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.2 | 189.8 | (69.3-413.1) |  | Male | 5 | 3.2 | 155.2 | (50.0-362.2) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.9 | 101.3 | (46.2-192.3) |
| Female | 71 | 61.2 | 116.0 | (90.6-146.3) |  | Female | 15 | 6.9 | 217.6 | (121.7-358.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.2 | 85.6 | (34.3-176.4) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.0 | 165.3 | (53.3-385.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 16.7 | 89.8 | (50.2-148.1) |  |  |  |  |  |  |
| Female | 19 | 13.8 | 138.0 | (83.1-215.5) |  | Female | 5 | 5.1 | 97.7 | (31.5-227.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.2 | nc | (nc-nc) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.5 | 132.2 | (48.3-287.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 48 | 54.5 | 88.0 | (64.9-116.7) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.3 | 85.8 | (36.9-169.1) |  | Male | 6 | 3.7 | 162.1 | (59.2-352.7) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 5 | 1.8 | 271.7 | (87.6-634.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.2 | 96.8 | (35.3-210.7) |  | Male | 1 | 4.3 | nc | (nc-nc) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 9 | 12.1 | 74.2 | (33.9-140.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 20 | 13.9 | 144.2 | (88.1-222.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 27.7 | 50.6 | (27.6-84.9) |  | Male | 164 | 207.5 | 79.0 | (67.4-92.1) |
| Female | 20 | 25.0 | 80.1 | (48.9-123.7) |  | Female | 209 | 192.7 | 108.5 | (94.3-124.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

34

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 14.4 | 76.5 | (38.1-136.9) |  | Male | 10 | 10.2 | 98.1 | (47.0-180.5) |
| Female | 3 | 5.8 | nc | (nc-nc) |  | Female | 9 | 8.7 | 102.9 | (47.0-195.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 6 | 3.2 | 184.9 | (67.5-402.4) |
| Female | 4 | 2.8 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 9.1 | 209.3 | (125.9-326.8) |
| Female | 69 | 71.5 | 96.4 | (75.0-122.1) |  | Female | 12 | 8.4 | 142.2 | (73.4-248.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.4 | 83.5 | (33.5-172.1) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 17.1 | 122.5 | (75.8-187.3) |  |  |  |  |  |  |
| Female | 20 | 16.9 | 118.3 | (72.2-182.7) |  | Female | 3 | 6.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.1 | 169.0 | (67.7-348.2) |  | Male | 6 | 5.5 | 108.9 | (39.8-237.1) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 8 | 5.9 | 136.5 | (58.8-269.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 73 | 52.7 | 138.5 | (108.5-174.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.5 | 84.3 | (36.3-166.2) |  | Male | 5 | 3.7 | 135.0 | (43.5-315.0) |
| Female | 5 | 5.6 | 89.9 | (29.0-209.9) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.3 | 79.5 | (25.6-185.6) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 16 | 13.9 | 114.9 | (65.6-186.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.0 | 99.4 | (36.3-216.4) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 17 | 16.3 | 104.4 | (60.8-167.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 26.7 | 116.3 | (79.0-165.0) |  | Male | 246 | 207.3 | 118.7 | (104.3-134.5) |
| Female | 22 | 31.4 | 70.0 | (43.9-106.0) |  | Female | 211 | 232.1 | 90.9 | (79.1-104.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

35

# Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 28.2 | 78.1 | (48.9-118.3) |  | Male | 16 | 17.5 | 91.5 | (52.3-148.6) |
| Female | 3 | 10.1 | nc | (nc-nc) |  | Female | 6 | 13.9 | 43.2 | (15.8-94.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.2 | 114.7 | (41.9-249.6) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 4 | 4.5 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.0 | nc | (nc-nc) |  | Male | 18 | 15.8 | 113.9 | (67.5-180.0) |
| Female | 125 | 111.3 | 112.3 | (93.4-133.8) |  | Female | 8 | 14.1 | 56.7 | (24.4-111.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 12.6 | 39.7 | (12.8-92.6) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 6 | 5.9 | 101.6 | (37.1-221.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 30.0 | 69.9 | (43.2-106.8) |  |  |  |  |  |  |
| Female | 23 | 29.8 | 77.3 | (49.0-115.9) |  | Female | 13 | 9.5 | 136.2 | (72.5-233.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.0 | 71.7 | (23.1-167.3) |  | Male | 12 | 9.9 | 121.5 | (62.7-212.2) |
| Female | 6 | 2.0 | 307.6 | (112.3-669.6) |  | Female | 11 | 10.3 | 107.0 | (53.3-191.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 76 | 82.7 | 91.9 | (72.4-115.1) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 15.0 | 79.9 | (41.2-139.6) |  | Male | 5 | 6.7 | 74.5 | (24.0-173.9) |
| Female | 3 | 8.9 | nc | (nc-nc) |  | Female | 7 | 4.0 | 173.7 | (69.6-358.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  | Male | 6 | 3.5 | 173.1 | (63.2-376.7) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 11.3 | nc | (nc-nc) |  | Male | 8 | 6.7 | 119.1 | (51.3-234.6) |
| Female | 5 | 8.2 | 60.7 | (19.5-141.6) |  | Female | 20 | 20.8 | 96.2 | (58.7-148.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 9.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 26 | 24.5 | 106.3 | (69.4-155.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 49.0 | 67.4 | (46.4-94.7) |  | Male | 289 | 352.1 | 82.1 | (72.9-92.1) |
| Female | 35 | 52.3 | 67.0 | (46.6-93.1) |  | Female | 334 | 375.3 | 89.0 | (79.7-99.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

36

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  | Male | 5 | 4.4 | 114.0 | (36.7-266.0) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 6 | 2.8 | 216.4 | (79.0-471.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 27 | 23.3 | 116.1 | (76.5-168.9) |  | Female | 6 | 2.4 | 247.0 | (90.2-537.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 7.2 | 138.2 | (66.1-254.1) |  |  |  |  |  |  |
| Female | 6 | 4.8 | 124.6 | (45.5-271.2) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 18 | 22.1 | 81.5 | (48.3-128.8) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.6 | (31.4-227.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 9 | 5.1 | 178.2 | (81.3-338.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 12.4 | 88.8 | (44.3-158.9) |  | Male | 73 | 89.3 | 81.8 | (64.1-102.8) |
| Female | 9 | 8.5 | 105.6 | (48.2-200.5) |  | Female | 88 | 70.7 | 124.6 | (99.9-153.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

37

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 6 | 2.5 | 238.1 | (87.0-518.3) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 12 | 13.8 | 87.2 | (45.0-152.3) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 10 | 12.3 | 81.3 | (38.9-149.6) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.1 | 160.5 | (51.7-374.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 7.2 | 111.7 | (48.1-220.2) |  | Male | 55 | 51.4 | 106.9 | (80.5-139.2) |
| Female | 5 | 6.3 | 79.4 | (25.6-185.2) |  | Female | 39 | 44.6 | 87.4 | (62.1-119.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

38

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 1.9 | 257.8 | (83.1-601.7) |
| Female | 10 | 12.1 | 82.5 | (39.5-151.7) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 14 | 10.6 | 131.9 | (72.1-221.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 6.3 | 95.5 | (34.9-207.9) |  | Male | 40 | 43.9 | 91.1 | (65.1-124.0) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 36 | 40.0 | 89.9 | (63.0-124.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

39

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 42.5 | 122.3 | (91.3-160.4) |  | Male | 40 | 26.8 | 149.1 | (106.5-203.0) |
| Female | 22 | 16.4 | 134.3 | (84.1-203.3) |  | Female | 31 | 22.8 | 136.0 | (92.4-193.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 8.1 | 159.6 | (84.9-272.9) |  | Male | 10 | 8.6 | 116.9 | (56.0-215.0) |
| Female | 6 | 7.2 | 83.1 | (30.4-181.0) |  | Female | 6 | 7.5 | 80.2 | (29.3-174.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 24 | 24.0 | 99.8 | (63.9-148.5) |
| Female | 180 | 180.9 | 99.5 | (85.5-115.2) |  | Female | 19 | 23.0 | 82.6 | (49.7-128.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 29 | 20.0 | 145.1 | (97.2-208.5) |
| Female | 5 | 6.0 | 83.3 | (26.8-194.3) |  | Female | 12 | 9.7 | 123.1 | (63.5-215.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 45.7 | 72.2 | (49.7-101.4) |  |  |  |  |  |  |
| Female | 49 | 48.1 | 101.8 | (75.3-134.6) |  | Female | 15 | 15.7 | 95.3 | (53.3-157.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 10.8 | 110.8 | (57.2-193.5) |  | Male | 17 | 15.1 | 112.8 | (65.7-180.6) |
| Female | 5 | 3.3 | 153.8 | (49.6-358.9) |  | Female | 17 | 16.9 | 100.5 | (58.5-161.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 158 | 130.8 | 120.8 | (102.7-141.1) |
| Female | 0 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 23.3 | 120.3 | (79.9-173.8) |  | Male | 4 | 10.2 | nc | (nc-nc) |
| Female | 18 | 14.3 | 126.0 | (74.6-199.1) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 6.2 | 144.7 | (66.1-274.8) |  | Male | 8 | 5.8 | 136.9 | (58.9-269.7) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 17.2 | 156.7 | (103.2-228.0) |  | Male | 12 | 10.6 | 113.2 | (58.4-197.8) |
| Female | 20 | 13.3 | 150.5 | (91.9-232.4) |  | Female | 30 | 33.9 | 88.4 | (59.7-126.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 14.6 | 95.7 | (52.3-160.5) |  |  |  |  |  |  |
| Female | 9 | 5.4 | 168.1 | (76.7-319.2) |  | Female | 38 | 40.7 | 93.4 | (66.1-128.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 85 | 74.7 | 113.7 | (90.8-140.6) |  | Male | 636 | 544.3 | 116.8 | (107.9-126.3) |
| Female | 89 | 85.1 | 104.6 | (84.0-128.7) |  | Female | 653 | 611.7 | 106.7 | (98.7-115.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

40

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 40.2 | 139.2 | (105.2-180.8) |  | Male | 28 | 27.2 | 102.9 | (68.3-148.7) |
| Female | 15 | 13.6 | 110.5 | (61.8-182.2) |  | Female | 23 | 20.7 | 111.2 | (70.5-166.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 13 | 8.6 | 151.7 | (80.7-259.5) |  | Male | 11 | 8.7 | 125.8 | (62.7-225.1) |
| Female | 5 | 6.7 | 75.2 | (24.2-175.5) |  | Female | 6 | 6.4 | 94.2 | (34.4-205.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 23 | 24.4 | 94.1 | (59.6-141.2) |
| Female | 177 | 168.0 | 105.3 | (90.4-122.1) |  | Female | 19 | 19.9 | 95.5 | (57.5-149.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 21.6 | 83.4 | (49.4-131.9) |
| Female | 5 | 5.9 | 84.3 | (27.2-196.7) |  | Female | 10 | 8.5 | 117.6 | (56.3-216.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 46.4 | 81.9 | (58.0-112.5) |  |  |  |  |  |  |
| Female | 57 | 40.6 | 140.5 | (106.4-182.1) |  | Female | 12 | 14.1 | 84.8 | (43.8-148.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 11.1 | 90.2 | (43.2-165.9) |  | Male | 13 | 14.9 | 87.5 | (46.5-149.6) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 9 | 13.9 | 64.9 | (29.6-123.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 3.5 | 171.1 | (62.5-372.5) |  | Male | 130 | 139.4 | 93.2 | (77.9-110.7) |
| Female | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 24.9 | 116.3 | (77.9-167.1) |  | Male | 9 | 10.1 | 89.4 | (40.8-169.8) |
| Female | 8 | 12.9 | 61.9 | (26.6-121.9) |  | Female | 8 | 5.5 | 146.3 | (63.0-288.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 6.5 | nc | (nc-nc) |  | Male | 5 | 6.6 | 76.0 | (24.5-177.4) |
| Female | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 17.0 | 164.3 | (109.1-237.4) |  | Male | 15 | 12.0 | 125.0 | (69.9-206.1) |
| Female | 19 | 11.5 | 164.6 | (99.1-257.1) |  | Female | 35 | 33.2 | 105.4 | (73.4-146.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 15.4 | 78.1 | (40.3-136.5) |  |  |  |  |  |  |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 39 | 37.1 | 105.1 | (74.7-143.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 72.7 | 108.7 | (86.0-135.5) |  | Male | 567 | 555.5 | 102.1 | (93.8-110.8) |
| Female | 106 | 73.4 | 144.3 | (118.2-174.6) |  | Female | 593 | 545.6 | 108.7 | (100.1-117.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

41

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 7.2 | 153.1 | (76.3-274.0) |  | Male | 6 | 5.2 | 115.4 | (42.2-251.3) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 6 | 4.8 | 124.1 | (45.3-270.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 28 | 39.7 | 70.5 | (46.8-101.9) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 8.8 | 102.2 | (46.7-194.1) |  |  |  |  |  |  |
| Female | 7 | 9.6 | 72.8 | (29.2-150.0) |  | Female | 5 | 3.3 | 149.4 | (48.2-348.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 2.1 | 286.9 | (104.8-624.5) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 26 | 26.3 | 98.8 | (64.5-144.8) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 6 | 2.6 | 229.8 | (83.9-500.2) |  | Female | 3 | 7.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 8.7 | 80.1 | (32.1-165.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 13.3 | 135.5 | (80.2-214.1) |  | Male | 117 | 105.0 | 111.5 | (92.2-133.6) |
| Female | 11 | 16.0 | 68.7 | (34.2-122.9) |  | Female | 111 | 126.7 | 87.6 | (72.1-105.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

42

# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 4 | 5.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 5.4 | 112.1 | (40.9-244.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 19 | 19.3 | 98.6 | (59.3-154.0) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 17 | 17.0 | 99.7 | (58.1-159.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

43

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.0 | 168.7 | (54.4-393.7) |
| Female | 28 | 19.4 | 144.6 | (96.1-209.0) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.7 | 87.4 | (28.2-203.8) |  |  |  |  |  |  |
| Female | 5 | 3.9 | 128.8 | (41.5-300.6) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 21 | 16.6 | 126.5 | (78.3-193.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 8 | 4.3 | 186.7 | (80.4-367.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 8.8 | nc | (nc-nc) |  | Male | 58 | 67.0 | 86.6 | (65.7-111.9) |
| Female | 5 | 7.0 | 71.8 | (23.1-167.4) |  | Female | 60 | 57.8 | 103.9 | (79.3-133.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

44

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 338 | 462.6 | 73.1 | (65.5-81.3) |  | Male | 249 | 315.3 | 79.0 | (69.5-89.4) |
| Female | 143 | 181.6 | 78.8 | (66.4-92.8) |  | Female | 205 | 290.5 | 70.6 | (61.2-80.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 74 | 109.4 | 67.6 | (53.1-84.9) |  | Male | 107 | 96.7 | 110.7 | (90.7-133.8) |
| Female | 71 | 93.2 | 76.1 | (59.5-96.1) |  | Female | 124 | 83.6 | 148.3 | (123.3-176.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 15 | 16.4 | 91.7 | (51.3-151.2) |  | Male | 265 | 285.3 | 92.9 | (82.0-104.8) |
| Female | 1909 | 2115.3 | 90.2 | (86.2-94.4) |  | Female | 252 | 267.3 | 94.3 | (83.0-106.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 265 | 232.9 | 113.8 | (100.5-128.3) |
| Female | 88 | 83.2 | 105.8 | (84.8-130.3) |  | Female | 107 | 111.7 | 95.8 | (78.5-115.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 557 | 519.1 | 107.3 | (98.6-116.6) |  |  |  |  |  |  |
| Female | 581 | 542.1 | 107.2 | (98.6-116.3) |  | Female | 187 | 185.7 | 100.7 | (86.8-116.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 122 | 120.9 | 100.9 | (83.8-120.5) |  | Male | 163 | 167.1 | 97.5 | (83.1-113.7) |
| Female | 32 | 35.6 | 89.8 | (61.4-126.7) |  | Female | 176 | 184.2 | 95.5 | (81.9-110.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 58 | 58.4 | 99.4 | (75.4-128.5) |  | Male | 1787 | 1465.8 | 121.9 | (116.3-127.7) |
| Female | 32 | 51.5 | 62.2 | (42.5-87.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 235 | 274.4 | 85.6 | (75.0-97.3) |  | Male | 173 | 114.2 | 151.5 | (129.8-175.9) |
| Female | 170 | 167.4 | 101.6 | (86.9-118.0) |  | Female | 118 | 73.9 | 159.8 | (132.2-191.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 90 | 70.3 | 128.0 | (102.9-157.3) |  | Male | 102 | 119.3 | 85.5 | (69.7-103.8) |
| Female | 17 | 22.6 | 75.3 | (43.9-120.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 174 | 206.6 | 84.2 | (72.2-97.7) |  | Male | 149 | 145.5 | 102.4 | (86.6-120.2) |
| Female | 145 | 162.3 | 89.3 | (75.4-105.1) |  | Female | 451 | 490.0 | 92.0 | (83.7-100.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 257 | 165.8 | 155.0 | (136.6-175.1) |  |  |  |  |  |  |
| Female | 95 | 60.9 | 155.9 | (126.1-190.6) |  | Female | 435 | 464.2 | 93.7 | (85.1-102.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 874 | 820.0 | 106.6 | (99.6-113.9) |  | Male | 6570 | 6276.4 | 104.7 | (102.2-107.2) |
| Female | 875 | 953.2 | 91.8 | (85.8-98.1) |  | Female | 6789 | 7191.1 | 94.4 | (92.2-96.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

45

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 38 | 29.7 | 127.9 | (90.5-175.6) |  | Male | 25 | 17.6 | 142.1 | (91.9-209.8) |
| Female | 9 | 10.9 | 82.7 | (37.7-156.9) |  | Female | 14 | 13.0 | 108.0 | (59.0-181.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.9 | nc | (nc-nc) |  | Male | 9 | 5.8 | 154.4 | (70.4-293.1) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 13 | 15.8 | 82.2 | (43.7-140.5) |
| Female | 87 | 107.0 | 81.3 | (65.1-100.3) |  | Female | 8 | 14.4 | 55.5 | (23.9-109.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 12.5 | 128.5 | (73.4-208.6) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 6 | 6.0 | 100.7 | (36.8-219.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 30.0 | 86.5 | (56.5-126.8) |  |  |  |  |  |  |
| Female | 28 | 30.8 | 91.0 | (60.5-131.5) |  | Female | 12 | 9.4 | 128.2 | (66.2-224.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 7.3 | 165.0 | (85.2-288.2) |  | Male | 8 | 10.2 | 78.2 | (33.7-154.0) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 9 | 11.1 | 81.1 | (37.0-154.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 85 | 86.2 | 98.6 | (78.8-122.0) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 14.8 | 67.7 | (32.4-124.5) |  | Male | 7 | 6.9 | 101.3 | (40.6-208.7) |
| Female | 8 | 8.8 | 91.0 | (39.2-179.3) |  | Female | 5 | 4.2 | 118.8 | (38.3-277.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 4.2 | 237.1 | (113.5-436.0) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 11.2 | 44.7 | (14.4-104.3) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 5 | 8.1 | 61.5 | (19.8-143.5) |  | Female | 21 | 16.5 | 127.0 | (78.6-194.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.5 | 73.4 | (29.4-151.3) |  |  |  |  |  |  |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 22 | 24.2 | 91.0 | (57.0-137.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 52.1 | 111.3 | (84.5-143.9) |  | Male | 369 | 359.9 | 102.5 | (92.3-113.6) |
| Female | 61 | 56.1 | 108.7 | (83.1-139.6) |  | Female | 335 | 372.3 | 90.0 | (80.6-100.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

46

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 22 | 20.4 | 107.6 | (67.4-163.0) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.7 | 87.8 | (28.3-204.9) |  |  |  |  |  |  |
| Female | 6 | 4.3 | 138.1 | (50.4-300.5) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 15 | 18.2 | 82.2 | (46.0-135.6) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 8.7 | 80.5 | (32.3-165.9) |  | Male | 61 | 69.0 | 88.4 | (67.6-113.5) |
| Female | 9 | 7.8 | 116.0 | (52.9-220.2) |  | Female | 68 | 62.5 | 108.8 | (84.5-137.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

47

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 9.4 | 63.6 | (23.2-138.4) |  | Male | 13 | 6.3 | 206.6 | (109.9-353.3) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 9 | 4.3 | 206.9 | (94.4-392.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.6 | 89.3 | (28.8-208.5) |
| Female | 43 | 37.0 | 116.3 | (84.1-156.6) |  | Female | 3 | 4.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 5.0 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 10.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 8.8 | 79.3 | (31.8-163.3) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 43 | 33.3 | 129.0 | (93.3-173.8) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 3.8 | 130.0 | (41.9-303.4) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 9 | 6.6 | 137.3 | (62.6-260.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 8.5 | 70.6 | (25.8-153.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 17.6 | 51.1 | (23.3-96.9) |  | Male | 109 | 129.3 | 84.3 | (69.2-101.7) |
| Female | 10 | 16.6 | 60.3 | (28.9-110.8) |  | Female | 119 | 119.6 | 99.5 | (82.4-119.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

48

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.4 | 110.7 | (40.4-240.9) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 8 | 2.3 | 353.6 | (152.3-696.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 27 | 18.5 | 146.0 | (96.2-212.5) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 4.8 | 125.9 | (46.0-274.1) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 15 | 16.6 | 90.5 | (50.6-149.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 9.5 | nc | (nc-nc) |  | Male | 55 | 69.5 | 79.1 | (59.6-103.0) |
| Female | 5 | 8.1 | 62.0 | (20.0-144.7) |  | Female | 68 | 60.7 | 112.0 | (87.0-142.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

49

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 46 | 39.7 | 115.9 | (84.9-154.6) |  | Male | 28 | 24.9 | 112.4 | (74.7-162.4) |
| Female | 22 | 16.3 | 134.8 | (84.4-204.1) |  | Female | 22 | 21.1 | 104.4 | (65.4-158.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 7.5 | nc | (nc-nc) |  | Male | 6 | 7.9 | 75.7 | (27.6-164.8) |
| Female | 6 | 6.7 | 89.4 | (32.6-194.5) |  | Female | 3 | 7.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 23 | 22.4 | 102.8 | (65.2-154.3) |
| Female | 195 | 165.9 | 117.5 | (101.6-135.2) |  | Female | 19 | 22.1 | 86.0 | (51.8-134.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 18.1 | 115.8 | (71.7-177.0) |
| Female | 7 | 5.5 | 128.2 | (51.3-264.1) |  | Female | 11 | 9.1 | 120.2 | (59.9-215.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 42.5 | 122.2 | (91.3-160.3) |  |  |  |  |  |  |
| Female | 60 | 47.8 | 125.4 | (95.7-161.5) |  | Female | 16 | 14.5 | 110.4 | (63.0-179.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 9.9 | 131.4 | (69.9-224.7) |  | Male | 15 | 14.0 | 107.4 | (60.0-177.1) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 19 | 16.8 | 113.1 | (68.0-176.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.9 | 170.0 | (54.8-396.8) |  | Male | 131 | 116.3 | 112.6 | (94.2-133.7) |
| Female | 5 | 2.5 | 200.6 | (64.6-468.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 21.3 | 103.4 | (64.8-156.5) |  | Male | 8 | 9.5 | 84.3 | (36.3-166.2) |
| Female | 13 | 13.5 | 96.6 | (51.4-165.2) |  | Female | 6 | 6.6 | 91.5 | (33.4-199.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 6 | 5.2 | 114.6 | (41.9-249.5) |
| Female | 6 | 1.9 | 319.5 | (116.7-695.5) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 16.1 | 80.6 | (42.9-137.8) |  | Male | 8 | 9.7 | 82.7 | (35.6-163.0) |
| Female | 19 | 13.0 | 146.0 | (87.9-228.0) |  | Female | 38 | 29.7 | 128.0 | (90.6-175.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 13.4 | 97.2 | (51.7-166.3) |  |  |  |  |  |  |
| Female | 5 | 5.1 | 97.5 | (31.4-227.6) |  | Female | 42 | 36.2 | 116.1 | (83.7-157.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 69.0 | 84.0 | (63.8-108.6) |  | Male | 517 | 499.2 | 103.6 | (94.8-112.9) |
| Female | 89 | 82.3 | 108.2 | (86.9-133.1) |  | Female | 655 | 576.4 | 113.6 | (105.1-122.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

50

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 18.5 | 97.4 | (57.7-153.9) |  | Male | 17 | 10.7 | 159.2 | (92.7-255.0) |
| Female | 6 | 7.0 | 86.2 | (31.5-187.7) |  | Female | 10 | 7.8 | 128.3 | (61.4-235.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 13 | 9.5 | 137.4 | (73.1-234.9) |
| Female | 93 | 66.5 | 139.8 | (112.9-171.3) |  | Female | 16 | 9.0 | 177.5 | (101.4-288.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.5 | 80.3 | (29.3-174.7) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 18.1 | 66.4 | (34.3-116.0) |  |  |  |  |  |  |
| Female | 18 | 18.9 | 95.5 | (56.5-150.9) |  | Female | 6 | 5.8 | 102.7 | (37.5-223.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 5 | 6.3 | 80.0 | (25.8-186.6) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 3 | 7.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 61 | 54.4 | 112.2 | (85.8-144.1) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 9.0 | nc | (nc-nc) |  | Male | 0 | 4.2 | nc | (nc-nc) |
| Female | 6 | 5.6 | 107.8 | (39.4-234.6) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.6 | 135.7 | (61.9-257.5) |  | Male | 0 | 3.3 | nc | (nc-nc) |
| Female | 7 | 5.0 | 140.4 | (56.3-289.3) |  | Female | 7 | 9.0 | 77.7 | (31.1-160.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.8 | 103.2 | (37.7-224.6) |  |  |  |  |  |  |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 13 | 15.7 | 82.8 | (44.0-141.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 33.3 | 99.2 | (68.3-139.4) |  | Male | 211 | 220.9 | 95.5 | (83.1-109.3) |
| Female | 25 | 36.5 | 68.4 | (44.3-101.0) |  | Female | 237 | 232.0 | 102.1 | (89.5-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

51

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 26.3 | 95.2 | (61.6-140.5) |  | Male | 13 | 17.2 | 75.5 | (40.2-129.1) |
| Female | 13 | 7.6 | 172.0 | (91.5-294.2) |  | Female | 19 | 11.6 | 164.1 | (98.8-256.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.6 | 126.1 | (50.5-259.8) |  | Male | 3 | 5.5 | nc | (nc-nc) |
| Female | 7 | 3.8 | 184.9 | (74.1-381.0) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 8 | 15.8 | 50.7 | (21.8-100.0) |
| Female | 79 | 90.7 | 87.1 | (69.0-108.5) |  | Female | 12 | 11.1 | 107.7 | (55.6-188.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 13.2 | 105.8 | (57.8-177.6) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 5 | 4.7 | 105.3 | (33.9-245.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 29.6 | 97.9 | (65.5-140.6) |  |  |  |  |  |  |
| Female | 17 | 22.4 | 75.8 | (44.1-121.4) |  | Female | 9 | 7.9 | 114.3 | (52.2-217.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  | Male | 10 | 9.5 | 105.0 | (50.3-193.0) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 8 | 7.7 | 103.8 | (44.7-204.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 79 | 84.1 | 94.0 | (74.4-117.1) |
| Female | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 15.4 | 64.9 | (31.1-119.4) |  | Male | 5 | 6.4 | 77.8 | (25.1-181.6) |
| Female | 8 | 7.0 | 113.9 | (49.0-224.4) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.0 | nc | (nc-nc) |  | Male | 0 | 4.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 11.2 | 53.4 | (19.5-116.2) |  | Male | 11 | 7.4 | 148.3 | (73.9-265.3) |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 30 | 18.5 | 162.4 | (109.5-231.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 9.4 | 160.3 | (89.6-264.4) |  |  |  |  |  |  |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 19 | 20.6 | 92.4 | (55.6-144.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 45.9 | 98.0 | (71.5-131.2) |  | Male | 318 | 349.7 | 90.9 | (81.2-101.5) |
| Female | 33 | 40.1 | 82.3 | (56.6-115.6) |  | Female | 295 | 300.4 | 98.2 | (87.3-110.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

52

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 0 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 18 | 17.7 | 101.7 | (60.3-160.8) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 9 | 14.8 | 60.6 | (27.7-115.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 2.5 | 281.1 | (112.6-579.2) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 7.2 | 97.0 | (38.9-199.9) |  | Male | 51 | 55.0 | 92.7 | (69.1-121.9) |
| Female | 4 | 7.7 | nc | (nc-nc) |  | Female | 38 | 56.0 | 67.8 | (48.0-93.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

53

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 80 | 83.9 | 95.3 | (75.6-118.7) |  | Male | 24 | 54.8 | 43.8 | (28.0-65.2) |
| Female | 36 | 31.8 | 113.2 | (79.3-156.8) |  | Female | 30 | 46.4 | 64.7 | (43.7-92.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 17 | 17.9 | 94.8 | (55.2-151.7) |  | Male | 11 | 17.5 | 62.9 | (31.4-112.6) |
| Female | 20 | 15.3 | 130.4 | (79.6-201.4) |  | Female | 18 | 14.6 | 123.5 | (73.2-195.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 48 | 49.5 | 96.9 | (71.4-128.5) |
| Female | 317 | 366.7 | 86.5 | (77.2-96.5) |  | Female | 38 | 45.5 | 83.5 | (59.1-114.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 38 | 41.7 | 91.2 | (64.5-125.1) |
| Female | 25 | 13.0 | 191.8 | (124.1-283.2) |  | Female | 23 | 19.2 | 119.7 | (75.9-179.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 113 | 92.8 | 121.7 | (100.3-146.4) |  |  |  |  |  |  |
| Female | 96 | 94.3 | 101.8 | (82.5-124.4) |  | Female | 44 | 31.5 | 139.6 | (101.4-187.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 22.1 | 95.2 | (58.9-145.6) |  | Male | 35 | 30.4 | 115.2 | (80.2-160.2) |
| Female | 6 | 6.3 | 95.8 | (35.0-208.5) |  | Female | 47 | 32.3 | 145.5 | (106.9-193.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 7.3 | 82.1 | (30.0-178.8) |  | Male | 260 | 271.1 | 95.9 | (84.6-108.3) |
| Female | 7 | 6.3 | 110.5 | (44.3-227.6) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 60 | 48.7 | 123.2 | (94.0-158.6) |  | Male | 31 | 20.5 | 151.0 | (102.6-214.3) |
| Female | 23 | 29.1 | 79.1 | (50.1-118.7) |  | Female | 12 | 12.8 | 94.1 | (48.6-164.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 18 | 12.9 | 139.9 | (82.9-221.1) |  | Male | 12 | 13.3 | 90.0 | (46.5-157.3) |
| Female | 4 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 36.0 | 83.3 | (56.2-118.9) |  | Male | 26 | 22.9 | 113.6 | (74.2-166.4) |
| Female | 17 | 27.3 | 62.4 | (36.3-99.8) |  | Female | 86 | 73.0 | 117.8 | (94.2-145.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 46 | 30.5 | 151.1 | (110.6-201.5) |  |  |  |  |  |  |
| Female | 13 | 10.5 | 123.6 | (65.8-211.4) |  | Female | 79 | 80.7 | 97.9 | (77.5-122.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 177 | 149.3 | 118.5 | (101.7-137.3) |  | Male | 1161 | 1116.0 | 104.0 | (98.1-110.2) |
| Female | 195 | 168.4 | 115.8 | (100.1-133.3) |  | Female | 1251 | 1227.0 | 102.0 | (96.4-107.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

54

# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 4.3 | 116.9 | (37.7-272.8) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 2.5 | nc | (nc-nc) |
| Female | 14 | 15.3 | 91.6 | (50.0-153.7) |  | Female | 5 | 2.0 | 252.6 | (81.4-589.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 4.1 | 123.2 | (39.7-287.5) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 11 | 14.7 | 75.1 | (37.4-134.3) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 7.9 | 101.5 | (43.7-199.9) |  | Male | 46 | 57.0 | 80.7 | (59.0-107.6) |
| Female | 13 | 7.6 | 171.9 | (91.5-294.0) |  | Female | 63 | 52.0 | 121.2 | (93.2-155.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

55

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 53.0 | 94.4 | (70.0-124.4) |  | Male | 49 | 34.0 | 144.3 | (106.8-190.8) |
| Female | 18 | 23.2 | 77.7 | (46.0-122.8) |  | Female | 37 | 32.9 | 112.5 | (79.2-155.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 10.7 | 84.5 | (38.5-160.3) |  | Male | 12 | 10.8 | 110.9 | (57.2-193.8) |
| Female | 14 | 10.5 | 133.0 | (72.7-223.2) |  | Female | 8 | 10.5 | 76.4 | (32.9-150.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 35 | 30.5 | 114.6 | (79.8-159.4) |
| Female | 228 | 247.9 | 92.0 | (80.4-104.7) |  | Female | 38 | 32.5 | 117.0 | (82.8-160.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 28 | 24.9 | 112.6 | (74.8-162.8) |
| Female | 3 | 8.8 | nc | (nc-nc) |  | Female | 7 | 13.5 | 51.7 | (20.7-106.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 56.2 | 58.8 | (40.4-82.5) |  |  |  |  |  |  |
| Female | 41 | 67.0 | 61.2 | (43.9-83.1) |  | Female | 32 | 21.9 | 146.3 | (100.1-206.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 13.7 | 36.4 | (11.7-85.1) |  | Male | 23 | 18.9 | 122.0 | (77.3-183.0) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 27 | 23.8 | 113.4 | (74.7-165.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 4.7 | 150.1 | (60.1-309.2) |  | Male | 159 | 170.4 | 93.3 | (79.4-109.0) |
| Female | 5 | 5.0 | 99.6 | (32.1-232.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 29.6 | 121.4 | (85.0-168.1) |  | Male | 11 | 12.7 | 86.3 | (43.0-154.4) |
| Female | 15 | 20.1 | 74.8 | (41.8-123.3) |  | Female | 6 | 9.1 | 65.8 | (24.0-143.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 8.0 | nc | (nc-nc) |  | Male | 11 | 8.9 | 123.3 | (61.5-220.6) |
| Female | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 30 | 21.7 | 138.1 | (93.1-197.1) |  | Male | 14 | 13.9 | 101.1 | (55.2-169.6) |
| Female | 29 | 19.4 | 149.9 | (100.3-215.2) |  | Female | 50 | 50.5 | 99.1 | (73.6-130.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 18.2 | 54.8 | (26.2-100.8) |  |  |  |  |  |  |
| Female | 5 | 7.5 | 66.8 | (21.5-155.8) |  | Female | 45 | 55.8 | 80.6 | (58.8-107.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 57 | 95.2 | 59.9 | (45.3-77.6) |  | Male | 629 | 692.6 | 90.8 | (83.9-98.2) |
| Female | 77 | 120.4 | 64.0 | (50.5-80.0) |  | Female | 759 | 857.8 | 88.5 | (82.3-95.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

56

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 7 | 11.3 | 61.8 | (24.8-127.4) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 7.8 | 90.1 | (36.1-185.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 25 | 30.5 | 82.1 | (53.1-121.2) |
| Female | 8 | 5.7 | 140.9 | (60.7-277.6) |  | Female | 31 | 37.9 | 81.7 | (55.5-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

57

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 31.5 | 63.4 | (38.7-98.0) |  | Male | 18 | 19.2 | 93.5 | (55.4-147.8) |
| Female | 6 | 10.6 | 56.4 | (20.6-122.8) |  | Female | 13 | 14.1 | 91.9 | (48.9-157.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 5.6 | 142.3 | (61.3-280.5) |  | Male | 7 | 6.1 | 114.0 | (45.7-235.0) |
| Female | 5 | 4.5 | 110.4 | (35.6-257.6) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 23 | 17.2 | 134.1 | (85.0-201.2) |
| Female | 132 | 116.4 | 113.4 | (94.9-134.5) |  | Female | 14 | 14.6 | 96.0 | (52.5-161.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 13.3 | 75.0 | (35.9-138.0) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 5 | 6.1 | 81.8 | (26.4-190.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 32.7 | 79.6 | (52.0-116.6) |  |  |  |  |  |  |
| Female | 26 | 30.5 | 85.4 | (55.7-125.1) |  | Female | 8 | 9.9 | 80.8 | (34.8-159.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 7.6 | nc | (nc-nc) |  | Male | 18 | 10.8 | 166.8 | (98.8-263.6) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 7 | 10.7 | 65.3 | (26.2-134.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 89 | 85.5 | 104.0 | (83.6-128.0) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 15.9 | 106.7 | (62.1-170.9) |  | Male | 4 | 7.4 | nc | (nc-nc) |
| Female | 5 | 9.3 | 53.7 | (17.3-125.2) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.3 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 12.3 | 129.6 | (74.0-210.5) |  | Male | 10 | 7.1 | 141.0 | (67.5-259.4) |
| Female | 5 | 8.4 | 59.7 | (19.2-139.3) |  | Female | 28 | 20.9 | 134.0 | (89.0-193.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 9.9 | 100.8 | (48.3-185.4) |  |  |  |  |  |  |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 32 | 25.5 | 125.4 | (85.8-177.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 54.8 | 74.8 | (53.7-101.5) |  | Male | 366 | 381.0 | 96.1 | (86.5-106.4) |
| Female | 55 | 57.2 | 96.2 | (72.5-125.2) |  | Female | 383 | 391.3 | 97.9 | (88.3-108.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

58

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 47 | 74.3 | 63.3 | (46.5-84.1) |  | Male | 51 | 50.5 | 101.0 | (75.2-132.8) |
| Female | 13 | 29.9 | 43.5 | (23.1-74.3) |  | Female | 46 | 48.0 | 95.9 | (70.2-127.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 25 | 17.9 | 139.6 | (90.3-206.1) |  | Male | 17 | 15.2 | 111.8 | (65.1-179.0) |
| Female | 14 | 15.1 | 92.5 | (50.5-155.2) |  | Female | 10 | 13.7 | 72.9 | (34.9-134.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 42 | 45.7 | 91.8 | (66.2-124.1) |
| Female | 318 | 339.2 | 93.7 | (83.7-104.6) |  | Female | 45 | 43.8 | 102.6 | (74.9-137.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 42 | 35.9 | 117.0 | (84.3-158.2) |
| Female | 7 | 13.6 | 51.6 | (20.7-106.3) |  | Female | 16 | 18.2 | 87.9 | (50.2-142.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 67 | 81.0 | 82.7 | (64.1-105.1) |  |  |  |  |  |  |
| Female | 67 | 87.1 | 76.9 | (59.6-97.7) |  | Female | 29 | 30.2 | 96.0 | (64.3-137.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 19.1 | 83.8 | (47.9-136.1) |  | Male | 32 | 26.4 | 121.1 | (82.8-171.0) |
| Female | 5 | 6.0 | 83.8 | (27.0-195.6) |  | Female | 25 | 30.4 | 82.4 | (53.3-121.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 10.7 | 74.8 | (32.2-147.4) |  | Male | 253 | 231.9 | 109.1 | (96.1-123.4) |
| Female | 4 | 9.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 31 | 43.0 | 72.1 | (49.0-102.4) |  | Male | 12 | 18.1 | 66.3 | (34.2-115.8) |
| Female | 17 | 27.1 | 62.7 | (36.5-100.4) |  | Female | 8 | 11.9 | 67.0 | (28.9-132.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 11.0 | nc | (nc-nc) |  | Male | 19 | 22.5 | 84.4 | (50.8-131.8) |
| Female | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 33.2 | 84.3 | (56.0-121.8) |  | Male | 27 | 23.6 | 114.4 | (75.3-166.4) |
| Female | 16 | 26.4 | 60.5 | (34.6-98.3) |  | Female | 85 | 81.0 | 104.9 | (83.8-129.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 25.5 | 62.8 | (35.9-102.0) |  |  |  |  |  |  |
| Female | 10 | 10.0 | 100.0 | (47.9-184.0) |  | Female | 65 | 75.8 | 85.8 | (66.2-109.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 109 | 131.9 | 82.6 | (67.9-99.7) |  | Male | 914 | 1001.6 | 91.3 | (85.4-97.4) |
| Female | 107 | 157.5 | 67.9 | (55.7-82.1) |  | Female | 981 | 1170.7 | 83.8 | (78.6-89.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

59

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 26.4 | 87.2 | (55.2-130.8) |  | Male | 20 | 16.4 | 122.2 | (74.6-188.8) |
| Female | 7 | 9.8 | 71.2 | (28.5-146.7) |  | Female | 14 | 12.8 | 109.0 | (59.5-182.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.8 | 103.7 | (33.4-242.1) |  | Male | 10 | 5.3 | 189.0 | (90.5-347.5) |
| Female | 6 | 4.1 | 145.0 | (52.9-315.5) |  | Female | 5 | 4.4 | 113.7 | (36.7-265.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 12 | 14.7 | 81.7 | (42.2-142.7) |
| Female | 106 | 104.3 | 101.6 | (83.2-122.9) |  | Female | 17 | 13.4 | 126.9 | (73.9-203.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 11.8 | 93.5 | (46.6-167.3) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 8 | 5.6 | 143.4 | (61.8-282.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 35 | 27.7 | 126.5 | (88.1-175.9) |  |  |  |  |  |  |
| Female | 30 | 28.3 | 105.9 | (71.4-151.2) |  | Female | 6 | 8.9 | 67.1 | (24.5-146.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.6 | 136.7 | (62.4-259.5) |  | Male | 8 | 9.3 | 86.1 | (37.1-169.6) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 9 | 10.0 | 89.6 | (40.9-170.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 85 | 78.3 | 108.5 | (86.7-134.2) |
| Female | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.0 | 64.1 | (29.3-121.8) |  | Male | 6 | 6.3 | 95.6 | (34.9-208.0) |
| Female | 5 | 8.4 | 59.4 | (19.1-138.5) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 10.4 | 172.4 | (102.1-272.4) |  | Male | 11 | 6.1 | 179.0 | (89.2-320.3) |
| Female | 5 | 7.8 | 64.2 | (20.7-149.8) |  | Female | 35 | 18.4 | 190.1 | (132.4-264.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 8.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 27 | 22.9 | 118.0 | (77.8-171.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 51 | 46.6 | 109.3 | (81.4-143.8) |  | Male | 357 | 330.0 | 108.2 | (97.2-120.0) |
| Female | 52 | 51.5 | 100.9 | (75.4-132.3) |  | Female | 373 | 355.1 | 105.0 | (94.6-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

60